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SUMMARY
The occurrence of a severe GvHD in a bone marrow transplanted male
A.M.L.-patient prompted us to investigate the in vitro activity of cyto-
toxic Τ cells of patients' lymphocytes post-transplantation. The male
A.M.L.-patient had been transplanted with an HLA identical female sib-
ling donor. Füll chimerism developed. Patients' lymphocytes post-trans-
plantation were stimulated with pre-transplant patients1 lymphocytes.
The 6 days effector cells were tested in a £ell Mediated Lympholysis
assay against randomly selected panel- and familydonors. Strong cyto-
lytic activity was observed against an antigen which is also present on
patients' own pre-transplant lymphocytes.
Preliminary findings show that the patients' effector cells recog-
nize an as yet unknown target determinant which is associated with HLA-
A2 in a randomly chosen panel of unrelated individuals and which shows
Mendelian segregation. The recognition of this determinant is HLA-de-
pendent but the location of the locus coding for it is unknown.
INTRODUCTION
Graft-versus-host reactions (GvHR) are probably caused by subpopu-
lations of donor Τ cells which differ for histocompatibility antigens
(1). It is also known that positive cytotoxic tests can be found before
and after bone marrow grafting between HLA identical siblings (2-4) .
Naturally, these observations can be attributable to non Major Histo-
compatibility Complex (MHC) antigens. We reported earlier on 3 cases by
which the peripheral blood lymphocytes of female aplastic anaemia pa-
tients were able to show HLA-restricted H-Y killing in a Cell Mediated
Lympholysis (CML) assay. These observations argue for the influence of
the, by the Y-chromosome coded, H-Y antigen as a non MHC minor trans-
plantation antigen (5-7). Furthermore, Sparkes et al. (8) reported on
the impact of the MNSs blood group antigen System on the occurrence of
graft-versus-host disease (GvHD).
In order to determine influences of non HLA-A to DR antigens on
the occurrence of GvHD, we investigated the in vitro cytotoxic activity
of pre- and post-transplant Τ lymphocytes of an acute myeloid leukaemia
(A.M.L.) patient suffering of a severe GvHD. We evaluated possible in-
fluences of the HLA and non HLA antigenic determinants.
In this study, we demonstrate the presence of an apparently HLA re-
stricted minor histocompatibility antigen which is demonstrable with the
CML test with patients' lymphocytes obtained after bone marrow trans-
plantation. The characteristics of this - sofar unknown - target deter-
minant will be discussed.
MATERIAL AND METHODS
The CML assay used has been previously described in detail (9). In
this study patients' post-transplant peripheral blood lymphocytes were
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sensitized in vitro for 6 d. with pre-transplant patients' lymphocytes.
The effector cells were thereafter tested against randomly selected
panel- and familydonors as target cells. Cytotoxicity (= the amount of
isotope released from the with 5 1Cr labeled target cells) was determined
and calculated according to the method described earlier (9).
Family "HA" (i.e. patients' family): parents, sibs, donor, patient
before and after transplantation were analyzed for all possible polymor-
phic genetic Systems: a) ABO blood groups, including Rhesus, MN, P,S,K,
Fy and Lewis; b) complement; c) 13 intracellular enzymes; d) group Five
System; e) sex and chromosomal patterns; f) HLA-A,-B,-C,-DR and -SB
antigens.
RESULTS AND DISCUSSION
Our study was initiated with the observation that post-transplant
lymphocytes from a bone marrow grafted A.M.L. patient (designated "HA")
demonstrated strong cytotoxicity against his own pre-transplant lympho-
cytes and several target cells from the panel (table I). Subsequently
experiments were performed, using the above-mentioned effector cells,
to analyse the specificity of the cytotoxic target determinant. Table
II shows the results of a panel study of randomly chosen individuals
tested sofar, which revealed a complete association with the HLA-A2 po-
sitive target cells. All target cells were lysed which carried the HLA-
A2 antigen.
To investigate whether or not this cytotoxic determinant is gene-
tically defined, familystudies were performed on the relatives of the
positive panelmembers. The results of the familystudies illustrated
Mendelian segregation. The cytotoxic determinant segregates in all 10
families tested sofar with the HLA-A2 haplotype. In contrast to these
observations 2 exceptions have been found in the family of the patient.
Absence of cytotoxicity was observed as well as on the lymphocytes of
the bone marrow donor (see table I) as on the lymphocytes of one out of
three haplo-identical siblings.
In search for the identity of the determinant which showed such
strong HLA-A2 restriction, we evaluated all possible polymorphic gene-
tic Systems which could be responsible for the HLA-A2 restricted lysis.
None of these Systems seemed to play a decisive role in the observed
cytotoxicity.
In conclusion, our data suggest that we may have defined an (to
our knowledge first demonstration in man) HLA restricted autosomal minor
histocompatibility antigen that might be similar to that described ear-
lier in mice (10). The cytotoxic determinant recognized by patients'
post-transplantation cytotoxic lymphocytes appeared after in vivo sensi-
tization (i.e. after bone marrow transplantation). It can be detected
in CML on PHA stimulated and unstimulated Τ cells and on Β cell lines
(EBV transformed). This example in man of a MHC restricted minor trans-
plantation antigen (designated HA) by which the target determinant would
only be detectable if it coexisted with a class I HLA antigen or an
antigen which is closely linked to it. The target determinant, which
shows a high gene frequency, may be coded for by 1) the HLA region, 2)
outside the HLA region but linked to it, or 3) another chromosome.
Since, cytotoxic lymphocyte reactions with this minor histocom-
patibility antigen appeared after bone marrow transplantation in a
patient suffering from severe GvHD, it is obvious to search for its
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contribution to the development of GvHR in man. This is especially true,
since the relevance of this topic has recently been demonstrated in
rodents (11).
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Table I. Lysis pattern of effector cellsx of patient "HA" against his
own.
n
target cells and target cells from unrelated individuals
Target cells HLA phenotypes % lysis
1
2
3
4
5
6
7
•Patient (pre-transplant)
" (post"transplant)
. Bone marrow donor
. Unrelated indiv.
11 If
11 11
11 11
2
2
2
3
1
2
?
Α
31
32
11
27
27
27
27
8
51
7
Β
62
62
62
40
44
62
27
C
1
1
1
2,3
3
2
DR
1,4
1,4
1,4
4
3,7
1,2
2,6
+59
- 1
- 3
+ 5
— 7
+26
+35
•yr
See materials and methods.
Table II. Possible evidence for an HLA-A2 associated target determinant
(panel study)
HLA-A2 positive
+ 9
CML
21
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